Mesoblast Limited (MESO)
NASDAQ: MESO · IEX Real-Time Price · USD
+0.11 (1.53%)
At close: Jun 13, 2024, 4:00 PM
+0.15 (2.06%)
After-hours: Jun 13, 2024, 4:09 PM EDT

Company Description

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.

The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases.

Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.

It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction.

It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain.

The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Mesoblast Limited
Mesoblast logo
Country Australia
Founded 2004
Industry Biotechnology
Sector Healthcare
Employees 83
CEO Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)

Contact Details

Level 38, 55 Collins Street
Melbourne, Victoria, C3 3000
Phone 613 9639 6036

Stock Details

Ticker Symbol MESO
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001345099
CUSIP Number 590717104
ISIN Number US5907174016
SIC Code 2836

Key Executives

Name Position
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board and Executive Director
Dr. Eric A. Rose M.D. Chief Medical Officer and Executive Director
Andrew Chaponnel B.Com. Interim Chief Finance Officer
Peter T. Howard B.Sc., L.L.B., LLB (Hons) General Counsel and Corporate Executive
Roger D. Brown BA Head of Spinal Orthopedic Disorders
Michael Schuster BSc, M.B.A., MS Head of Pharma Partnering
Geraldine Storton B.Sc., M.B.A., MMS Head of Regulatory Affairs and Quality Management
Justin Horst B.S. Head of Manufacturing
Niva Sivakumar B.Com., L.L.B. Joint Company Secretary
Paul Hughes BPHARM Joint Company Secretary

Latest SEC Filings

Date Type Title
Jun 4, 2024 6-K Report of foreign issuer
May 10, 2024 6-K Report of foreign issuer
May 3, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
May 3, 2024 6-K Report of foreign issuer
May 1, 2024 6-K Report of foreign issuer
Apr 26, 2024 424B3 Prospectus
Apr 24, 2024 EFFECT Notice of Effectiveness
Apr 19, 2024 UPLOAD Filing
Apr 17, 2024 6-K Report of foreign issuer
Apr 17, 2024 6-K Report of foreign issuer